Advertisement
Canada markets open in 3 hours 55 minutes
  • S&P/TSX

    22,259.47
    +312.06 (+1.42%)
     
  • S&P 500

    5,180.74
    +52.95 (+1.03%)
     
  • DOW

    38,852.27
    +176.59 (+0.46%)
     
  • CAD/USD

    0.7309
    -0.0012 (-0.16%)
     
  • CRUDE OIL

    78.69
    +0.21 (+0.27%)
     
  • Bitcoin CAD

    87,894.37
    -1,282.08 (-1.44%)
     
  • CMC Crypto 200

    1,332.70
    -32.42 (-2.38%)
     
  • GOLD FUTURES

    2,324.00
    -7.20 (-0.31%)
     
  • RUSSELL 2000

    2,060.67
    +24.95 (+1.23%)
     
  • 10-Yr Bond

    4.4890
    -0.0110 (-0.24%)
     
  • NASDAQ futures

    18,186.25
    -9.25 (-0.05%)
     
  • VOLATILITY

    13.51
    +0.02 (+0.15%)
     
  • FTSE

    8,302.19
    +88.70 (+1.08%)
     
  • NIKKEI 225

    38,835.10
    +599.03 (+1.57%)
     
  • CAD/EUR

    0.6791
    -0.0001 (-0.01%)
     

Company News For Oct 24, 2019

  • Alexion Pharmaceuticals Inc.’s ALXN shares soared 7.4% after reporting third-quarter 2020 adjusted earnings per share of $2.79, surpassing the Zacks Consensual Estimate of $2.49.

  • Anthem Inc. ANTM gained 1.3% after the company posted third-quarter 2019 adjusted earnings per share of $4.87, beating the Zacks Consensus Estimate of $4.84.

  • Shares of Thermo Fisher Scientific Inc. TMO surged 5.7% after posting third-quarter 2019 adjusted earnings per share of $2.94, outpacing the Zacks Consensus Estimate of $2.88.

  • Boston Scientific Corp. BSX shares climbed 5% after the company reported third-quarter 2019 adjusted earnings per share of $0.39, a penny above the Zacks Consensus Estimate.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Thermo Fisher Scientific Inc. (TMO) : Free Stock Analysis Report
 
Boston Scientific Corporation (BSX) : Free Stock Analysis Report
 
Alexion Pharmaceuticals, Inc. (ALXN) : Free Stock Analysis Report
 
Anthem, Inc. (ANTM) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research